Switzerland’s Roche Jan-Sept sales up by 7% on stronger demand

16 October 2012 08:13  [Source: ICIS news]

SINGAPORE (ICIS)--Swiss pharmaceuticals firm Roche said on Tuesday its total sales rose by 7% year on year to Swiss franc (Swfr) 33.7bn ($36.2bn) in January-September 2012 on the back of strong demand for its cancer medicines and its clinical lab business.

On a constant exchange-rate basis, its sales rose by 4% year on year in the first nine months of this year, Roche said in a statement.

“Group sales were strong in the US and in emerging markets, whereas in Western Europe sales growth declined slightly as expected,” it said.

“The weakening of the Swiss franc against the dollar and the Japanese yen, particularly in the third quarter, supported the sales performance in Swiss franc terms,” the company said.

For the full year of 2012, Roche projects a low-to-mid single-digit sales growth at constant exchange rates for the group and its pharmaceuticals division.

Sales by the firm’s diagnostics division is expected to again outpace the market for the full year, it added.

($1 = Swfr0.93)

By: Nurluqman Suratman

AddThis Social Bookmark Button

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly